BioMarin Pharmaceutical Statistics
Total Valuation
BMRN has a market cap or net worth of $11.19 billion. The enterprise value is $10.37 billion.
| Market Cap | 11.19B |
| Enterprise Value | 10.37B |
Important Dates
The last earnings date was Monday, August 4, 2025, after market close.
| Earnings Date | Aug 4, 2025 |
| Ex-Dividend Date | n/a |
Share Statistics
BMRN has 192.01 million shares outstanding. The number of shares has increased by 0.35% in one year.
| Current Share Class | 192.01M |
| Shares Outstanding | 192.01M |
| Shares Change (YoY) | +0.35% |
| Shares Change (QoQ) | +0.31% |
| Owned by Insiders (%) | 0.75% |
| Owned by Institutions (%) | 92.46% |
| Float | 179.60M |
Valuation Ratios
The trailing PE ratio is 17.15 and the forward PE ratio is 13.46. BMRN's PEG ratio is 0.75.
| PE Ratio | 17.15 |
| Forward PE | 13.46 |
| PS Ratio | 3.63 |
| Forward PS | 3.34 |
| PB Ratio | 1.86 |
| P/TBV Ratio | 2.00 |
| P/FCF Ratio | 16.11 |
| P/OCF Ratio | 14.60 |
| PEG Ratio | 0.75 |
Enterprise Valuation
The stock's EV/EBITDA ratio is 10.85, with an EV/FCF ratio of 14.92.
| EV / Earnings | 15.77 |
| EV / Sales | 3.38 |
| EV / EBITDA | 10.85 |
| EV / EBIT | 11.89 |
| EV / FCF | 14.92 |
Financial Position
The company has a current ratio of 5.56, with a Debt / Equity ratio of 0.10.
| Current Ratio | 5.56 |
| Quick Ratio | 3.34 |
| Debt / Equity | 0.10 |
| Debt / EBITDA | 0.62 |
| Debt / FCF | 0.87 |
| Interest Coverage | 78.64 |
Financial Efficiency
Return on equity (ROE) is 11.62% and return on invested capital (ROIC) is 8.37%.
| Return on Equity (ROE) | 11.62% |
| Return on Assets (ROA) | 7.50% |
| Return on Invested Capital (ROIC) | 8.37% |
| Return on Capital Employed (ROCE) | 12.88% |
| Revenue Per Employee | $1.01M |
| Profits Per Employee | $216,198 |
| Employee Count | 3,040 |
| Asset Turnover | 0.42 |
| Inventory Turnover | 0.44 |
Taxes
In the past 12 months, BMRN has paid $182.80 million in taxes.
| Income Tax | 182.80M |
| Effective Tax Rate | 21.76% |
Stock Price Statistics
The stock price has decreased by -34.52% in the last 52 weeks. The beta is 0.18, so BMRN's price volatility has been lower than the market average.
| Beta (5Y) | 0.18 |
| 52-Week Price Change | -34.52% |
| 50-Day Moving Average | 57.35 |
| 200-Day Moving Average | 62.98 |
| Relative Strength Index (RSI) | 50.03 |
| Average Volume (20 Days) | 2,468,269 |
Short Selling Information
The latest short interest is 5.15 million, so 2.68% of the outstanding shares have been sold short.
| Short Interest | 5.15M |
| Short Previous Month | 6.11M |
| Short % of Shares Out | 2.68% |
| Short % of Float | 2.87% |
| Short Ratio (days to cover) | 2.84 |
Income Statement
In the last 12 months, BMRN had revenue of $3.06 billion and earned $657.24 million in profits. Earnings per share was $3.40.
| Revenue | 3.06B |
| Gross Profit | 2.51B |
| Operating Income | 871.91M |
| Pretax Income | 298.68M |
| Net Income | 657.24M |
| EBITDA | 955.15M |
| EBIT | 871.91M |
| Earnings Per Share (EPS) | $3.40 |
Balance Sheet
The company has $1.43 billion in cash and $603.87 million in debt, giving a net cash position of $828.26 million or $4.31 per share.
| Cash & Cash Equivalents | 1.43B |
| Total Debt | 603.87M |
| Net Cash | 828.26M |
| Net Cash Per Share | $4.31 |
| Equity (Book Value) | 6.03B |
| Book Value Per Share | 31.39 |
| Working Capital | 3.12B |
Cash Flow
In the last 12 months, operating cash flow was $766.77 million and capital expenditures -$71.86 million, giving a free cash flow of $694.91 million.
| Operating Cash Flow | 766.77M |
| Capital Expenditures | -71.86M |
| Free Cash Flow | 694.91M |
| FCF Per Share | $3.62 |
Margins
Gross margin is 81.80%, with operating and profit margins of 28.46% and 21.45%.
| Gross Margin | 81.80% |
| Operating Margin | 28.46% |
| Pretax Margin | 27.42% |
| Profit Margin | 21.45% |
| EBITDA Margin | 31.18% |
| EBIT Margin | 28.46% |
| FCF Margin | 22.68% |
Dividends & Yields
BMRN does not appear to pay any dividends at this time.
| Dividend Per Share | n/a |
| Dividend Yield | n/a |
| Dividend Growth (YoY) | n/a |
| Years of Dividend Growth | n/a |
| Payout Ratio | n/a |
| Buyback Yield | -0.35% |
| Shareholder Yield | -0.35% |
| Earnings Yield | 5.87% |
| FCF Yield | 6.21% |
Analyst Forecast
The average price target for BMRN is $93.14, which is 59.76% higher than the current price. The consensus rating is "Buy".
| Price Target | $93.14 |
| Price Target Difference | 59.76% |
| Analyst Consensus | Buy |
| Analyst Count | 23 |
| Revenue Growth Forecast (5Y) | 7.84% |
| EPS Growth Forecast (5Y) | 28.07% |
Fair Value
There are several formulas that can be used to estimate the intrinsic value of a stock.
| Lynch Fair Value | |
| Lynch Upside | |
| Graham Number | |
| Graham Upside |
Stock Splits
This stock does not have any record of stock splits.
| Last Split Date | n/a |
| Split Type | n/a |
| Split Ratio | n/a |
Scores
BMRN has an Altman Z-Score of 6.89 and a Piotroski F-Score of 7.
| Altman Z-Score | 6.89 |
| Piotroski F-Score | 7 |